Antisense Oligonucleotides

Antisense oligonucleotides (ASOs) are being developed as treatments for rare genetic disorders such as SCN2A. What are they and how do they work? To help gain a better understanding of ASOs and their role we talk to Dr Stanley Crooke, founder of Ionis.

Hosted by Kris Pierce and David Cunnington, parents of Will, who has SCN2A.

Leave a review and subscribe via Apple Podcasts. 

You can also find SCN2A Insights on Spotify, and Google Podcasts or in your podcast app

Links

American Epilepsy Society meetingSummary of ASO presentations at AESDr Ana Mignorance - @CNSDrugHunter on TwitterIonis Webinar on ASO treatment for gain of function SCN2A

See omnystudio.com/listener for privacy information.

Listen to SCN2A Insights to keep up to date with the latest research in SCN2A, genetic epilepsy and rare genetic disorders. Hosted by Ms Kris Pierce, RARE Global Advocacy Leadership Council member, and Dr David Cunnington, parents of Will, who has SCN2A.

• No. of episodes: 28
• Latest episode: 2022-02-20
• Health & Fitness Science

Where can you listen?